• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠脑中的胃抑制性多肽(GIP)结合位点。

Gastric inhibitory polypeptide (GIP) binding sites in rat brain.

作者信息

Kaplan A M, Vigna S R

机构信息

Department of Cell Biology, Duke University Medical Center, Durham, NC 27710.

出版信息

Peptides. 1994;15(2):297-302. doi: 10.1016/0196-9781(94)90016-7.

DOI:10.1016/0196-9781(94)90016-7
PMID:8008635
Abstract

Synthetic porcine gastric inhibitory polypeptide (GIP) was iodinated and purified by reverse-phase HPLC and used to localize saturable [125I]GIP binding sites by radioligand binding to frozen sections of rat brain followed by autoradiography. Saturable [125I]GIP binding sites were expressed in several brain regions including cerebral cortex, anterior olfactory nucleus, lateral septal nucleus, subiculum, inferior colliculus, and inferior olive. Saturable [125I]GIP binding was time dependent, reversible, high affinity, and specific for GIP. Scatchard analysis of equilibrium binding resulted in an estimated dissociation constant (Kd) of 16-62 pM for the rat brain [125I]GIP binding sites. Peptides with amino acid sequences similar to GIP such as secretin, vasoactive intestinal polypeptide (VIP), glucagon, and peptide histidine isoleucine (PHI) only partially inhibited saturable [125I]GIP binding at concentrations approximately 10,000-100,000-fold higher than GIP. Saturable [125I]GIP binding was not observed in other rat organs surveyed such as spinal cord, pituitary, stomach, small intestine, colon, pancreas, liver, heart, or skeletal muscle. We conclude that a saturable [125I]GIP binding site with the pharmacological properties of an authentic GIP receptor is expressed in certain regions of the rat brain.

摘要

合成猪胃抑制多肽(GIP)经碘化后通过反相高效液相色谱法纯化,并用于通过放射性配体与大鼠脑冰冻切片结合后进行放射自显影来定位可饱和的[125I]GIP结合位点。可饱和的[125I]GIP结合位点在包括大脑皮层、前嗅核、外侧隔核、海马下脚、下丘和下橄榄核在内的几个脑区中表达。可饱和的[125I]GIP结合具有时间依赖性、可逆性、高亲和力且对GIP具有特异性。对平衡结合进行Scatchard分析得出,大鼠脑[125I]GIP结合位点的估计解离常数(Kd)为16 - 62 pM。与GIP氨基酸序列相似的肽,如促胰液素、血管活性肠多肽(VIP)、胰高血糖素和肽组氨酸异亮氨酸(PHI),在浓度比GIP高约10,000 - 100,000倍时仅部分抑制可饱和的[125I]GIP结合。在所检测的其他大鼠器官如脊髓、垂体、胃、小肠、结肠、胰腺、肝脏、心脏或骨骼肌中未观察到可饱和的[125I]GIP结合。我们得出结论,在大鼠脑的某些区域表达了具有真实GIP受体药理学特性的可饱和[125I]GIP结合位点。

相似文献

1
Gastric inhibitory polypeptide (GIP) binding sites in rat brain.大鼠脑中的胃抑制性多肽(GIP)结合位点。
Peptides. 1994;15(2):297-302. doi: 10.1016/0196-9781(94)90016-7.
2
Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain.大鼠脑中[单[125I]碘-Tyr10,MetO17]血管活性肠肽结合位点的放射自显影图谱
Neuroscience. 1987 Nov;23(2):539-65. doi: 10.1016/0306-4522(87)90075-3.
3
Analysis of the immunomodulatory properties of the secretin-glucagon family of peptides on mouse lymphoid cell functions and the demonstration of specific receptors on T cells.促胰液素-胰高血糖素肽家族对小鼠淋巴细胞功能的免疫调节特性分析及T细胞上特异性受体的证实。
Immunol Invest. 1987 Nov;16(7):555-77. doi: 10.3109/08820138709087102.
4
Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections.垂体腺苷酸环化酶激活多肽(PACAP)的结合位点:与大鼠脑切片中血管活性肠多肽(VIP)结合位点定位的比较。
Brain Res. 1992 Mar 13;575(1):113-23. doi: 10.1016/0006-8993(92)90430-h.
5
Characterization of VIP-and helodermin-preferring receptors on rat platelets.
Regul Pept. 1996 Jul 5;63(2-3):99-103. doi: 10.1016/0167-0115(96)00026-2.
6
Interaction of gastric inhibitory polypeptide (GIP) with the insulin-secreting pancreatic beta cell line, In lll: characteristics of GIP binding sites.
Life Sci. 1985 Mar 4;36(9):807-13. doi: 10.1016/0024-3205(85)90203-6.
7
Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties.大鼠胰岛葡萄糖依赖性促胰岛素多肽受体的功能表达:配体结合及细胞内信号传导特性
Endocrinology. 1995 Oct;136(10):4629-39. doi: 10.1210/endo.136.10.7664683.
8
[Demonstration of specific receptors for gastric inhibitory peptide (GIP)].
C R Seances Acad Sci III. 1983;297(12):563-5.
9
Secretin receptors mediating rat forestomach relaxation.介导大鼠前胃松弛的促胰液素受体。
Am J Physiol. 1993 May;264(5 Pt 1):G863-7. doi: 10.1152/ajpgi.1993.264.5.G863.
10
Gastric inhibitory polypeptide stimulates glucocorticoid secretion in rats, acting through specific receptors coupled with the adenylate cyclase-dependent signaling pathway.胃抑制性多肽通过与腺苷酸环化酶依赖性信号通路偶联的特异性受体,刺激大鼠糖皮质激素的分泌。
Peptides. 1999;20(5):589-94. doi: 10.1016/s0196-9781(99)00011-x.

引用本文的文献

1
Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.肠促胰岛素激素GLP-1和GIP使阿尔茨海默病和帕金森病患者大脑中的能量利用正常化并减轻炎症:从GLP-1受体激动剂的重新利用到新型GLP-1/GIP双受体激动剂作为潜在的疾病修饰疗法。
CNS Drugs. 2025 Sep 12. doi: 10.1007/s40263-025-01226-z.
2
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight.胰高血糖素样肽-1和葡萄糖依赖性促胰岛素多肽激动剂的下游相互作用是对体重产生协同作用所必需的。
Mol Metab. 2025 Sep;99:102214. doi: 10.1016/j.molmet.2025.102214. Epub 2025 Jul 16.
3
The evolution of the therapeutic concept 'GIP receptor antagonism'.治疗概念“GIP受体拮抗作用”的演变
Front Endocrinol (Lausanne). 2025 May 21;16:1570603. doi: 10.3389/fendo.2025.1570603. eCollection 2025.
4
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice.GIPR抗体/GLP-1肽-抗体偶联物在肥胖小鼠中实现额外体重减轻需要脑GIPR和GLP-1R。
Nat Metab. 2025 Apr 29. doi: 10.1038/s42255-025-01295-w.
5
Incretin-based therapeutics for the treatment of neurodegenerative diseases.用于治疗神经退行性疾病的基于肠促胰岛素的疗法。
Nat Metab. 2025 Apr;7(4):679-696. doi: 10.1038/s42255-025-01263-4. Epub 2025 Apr 10.
6
Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data.用于治疗2型糖尿病和肥胖症的双靶点和三靶点肠道肽激动剂即将问世。临床前和临床数据概述
Curr Obes Rep. 2025 Apr 11;14(1):34. doi: 10.1007/s13679-025-00623-1.
7
The role of GIPR in food intake control.胃抑制多肽受体(GIPR)在食物摄入控制中的作用。
Front Endocrinol (Lausanne). 2025 Mar 17;16:1532076. doi: 10.3389/fendo.2025.1532076. eCollection 2025.
8
Glucose-dependent insulinotropic polypeptide (GIP).葡萄糖依赖性促胰岛素多肽(GIP)。
Mol Metab. 2025 May;95:102118. doi: 10.1016/j.molmet.2025.102118. Epub 2025 Feb 28.
9
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease.DPP-4 抑制剂西他列汀和 PF-00734,200 减轻了帕金森病 6-OHDA 大鼠模型中的多巴胺能神经退行性变、神经炎症和行为障碍。
Geroscience. 2024 Oct;46(5):4349-4371. doi: 10.1007/s11357-024-01116-0. Epub 2024 Apr 2.
10
An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.一种具有位点特异性N端聚乙二醇化的失衡GLP-1R/GIPR共激动剂肽,以最大化代谢益处。
iScience. 2024 Mar 1;27(4):109377. doi: 10.1016/j.isci.2024.109377. eCollection 2024 Apr 19.